Back to results
US 2022/0054475 A1Published application
Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment
AssigneeAdvenchen Pharmaceuticals, LLC
InventorsGuoqing Paul Chen, Judy Chen, Zhe Li, Yingyin Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually.
Claims18
A regimen method to treat cancer in a subject in need thereof comprising:
- a standard platinum-based chemotherapeutic agent and another chemotherapeutic agent;
- or each individually;
- or an immunotherapeutic agent;
- in combing with AL3818 or its pharmaceutically acceptable salts in repeated cycles with the option of administration of maintenance mono therapy of AL3818 or its pharmaceutically acceptable salts.
1 more element
Dependencies are inferred from the claim text.